CNTX vs. TNGX, TRVI, BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, ITOS, and AQST
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Context Therapeutics vs.
Context Therapeutics (NASDAQ:CNTX) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
In the previous week, Context Therapeutics had 10 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Context Therapeutics and 0 mentions for Tango Therapeutics. Context Therapeutics' average media sentiment score of 0.21 beat Tango Therapeutics' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics has higher earnings, but lower revenue than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
Context Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Tango Therapeutics' return on equity of -49.64% beat Context Therapeutics' return on equity.
Context Therapeutics presently has a consensus target price of $6.33, indicating a potential upside of 527.06%. Tango Therapeutics has a consensus target price of $13.14, indicating a potential upside of 361.15%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Context Therapeutics is more favorable than Tango Therapeutics.
Context Therapeutics has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Tango Therapeutics received 7 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Context Therapeutics an outperform vote while only 73.68% of users gave Tango Therapeutics an outperform vote.
14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 3.0% of Context Therapeutics shares are held by insiders. Comparatively, 6.3% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Context Therapeutics beats Tango Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Context Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CNTX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free CNTX Stock Alerts